Sprint Fidelis implantable cardioverter-defibrillators lead patient management and survival: Single center study
Abstract
Background: Over the last several years significant rises in the use of implanted cardioverter-defibrillators (ICD) have also resulted in a number of associated complications. This number includes lead failure. Sprint Fidelis (SF) ICD lead is regarded as a lead with elevated failure risk. Every center acting in accordance with the guidelines should observe patients more thoroughly especially with recalled leads and run a registry of their follow-up. The aim of this research was to present follow-up of the patients with SF leads (types 6948, 6949) from a single implantation center.
Methods: There were 36 SF leads implanted in 36 patients. Mean follow-up period was 76 months (IQR 40.3–86.8). Patients were subjected to regular check-ups in 3 to 6 month intervals.
Results: Patients were implanted at a median age of 66.5 years and majority of them had ischemic cardiomyopathy (72%). A majority of the studied population were men (72.2%). Predominantly dual-chamber ICD (ICD-DR) were implanted (50% ICD-DR vs. 47.2% ICD-VR). The guidelines for management of patients implanted with SF were fully implemented. During the follow-up 14 (38.9%) patients died. No deaths were noted that could be attributed to lead failure. In 5 cases lead failure was identified and of these 4 leads were replaced. Median time from implantation to the detection of lead dysfunction was 52 months (IQR 49; 83). The symptoms of failure consisted of: inappropriate shocks, alternating ventricular lead signal, or loss of ventricular stimulation.
Conclusions: The follow-up of patients with recalled SF leads in a single center supports that implementation SF management guidelines could be effective in clinical practice.
Keywords: defibrillatorsimplantable (E07.305.250.159.175) lead failureSprint Fidelislead extractionlead survival
References
- Hauser RG, Kallinen LM, Almquist AK, et al. Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm. 2007; 4(7): 892–896.
- Medtronic. Urgent Medical Device Information: Sprint Fidelis Lead Patient Management. Recommendations.2007. http://www.medtronic.com/product-advisories/physician/sprint-fidelis/PROD-ADV-PHYS-OCT (2007-10-15).
- Kutarski A, Chudzik M, Mitkowski P, et al. Postępowanie w przypadku pacjentów z elektrodami z rodziny Sprint-Fidelis — wytyczne Zespołu Ekspertów Konsultanta Krajowego w dziedzinie kardiologii. Kardiol Pol. 2011; 69: 995–996.
- Catanchin A, Anderson L, Jones S, et al. When life-saving devices terminate life. J Cardiovasc Electrophysiol. 2008; 19(3): 316–318.
- Epstein AE, Carlson MD, Fogoros RN, et al. Classification of death in antiarrhythmia trials. J Am Coll Cardiol. 1996; 27(2): 433–442.
- Vollmann D, Woronowicz S, Kmiec L, et al. Passive-fixation lead failure rates and long-term patient mortality in subjects implanted with Sprint Fidelis electrodes. Europace. 2014; 16(2): 258–264.
- Birnie DH, Parkash R, Exner DV, et al. Clinical predictors of Fidelis lead failure: report from the Canadian Heart Rhythm Society Device Committee. Circulation. 2012; 125(10): 1217–1225.
- Hauser RG, Maisel WH, Friedman PA, et al. Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure: implications for patient management. Circulation. 2011; 123(4): 358–363.
- Morrison TB, Friedman PA, Kallinen LM, et al. Impact of implanted recalled sprint Fidelis lead on patient mortality. J Am Coll Cardiol. 2011; 58(3): 278–283.
- Brown J, Bilchick K, Alonso A, et al. OptiVol Impedance Threshold Crossing Predicts Patients with Higher Mortality or Hospitalization Risk Among Medicare Recipients. J Cardiac Failure. 2015; 21(8): S122.
- CareLINK Plus data: Sprint Fidelis model 6949 lead performance. http://wwwmedtroniccom/product-advisories/physician/sprint-fidelis/6949-LEAD-PERFORMANCE (January 2015).
- Cheung JW, Tobin-Hess A, Patel A, et al. Trends in Fidelis lead survival: transition from an exponential to linear pattern of lead failure over time. Circ Arrhythm Electrophysiol. 2012; 5(5): 906–912.
- Parsonnet V, Roelke M. The cephalic vein cutdown versus subclavian puncture for pacemaker/ICD lead implantation. Pacing Clin Electrophysiol. 1999; 22(5): 695–697.
- Frey SM, Sticherling C, Bucher U, et al. Long-term performance of the Medtronic Sprint Fidelis lead: a matter of lead type? Europace. 2012; 14(11): 1620–1623.
- Piot O, Deballon R, Nitu D, et al. Factors predicting Sprint Fidelis lead fracture: Results at 5 years from a French multicentre registry. Arch Cardiovasc Dis. 2015; 108(4): 220–226.
- Lovelock JD, Patel A, Mengistu A, et al. Generator exchange is associated with an increased rate of Sprint Fidelis lead failure. Heart Rhythm. 2012; 9(10): 1615–1618.
- Tzogias L, Bellavia D, Sharma S, et al. Natural history of the Sprint Fidelis lead: survival analysis from a large single-center study. J Interv Card Electrophysiol. 2012; 34(1): 37–44.
- Bernstein NE, Karam ET, Aizer A, et al. Right-sided implantation and subpectoral position are predisposing factors for fracture of a 6.6 French ICD lead. Pacing Clin Electrophysiol. 2012; 35(6): 659–664.
- Krahn AD, Bashir J, Birnie DH, et al. Impact of generator replacement on the risk of Fidelis lead fracture. Heart Rhythm. 2016; 13(8): 1618–1623.
- Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol. 2015; 65(16): 1605–1615.
- Ha ACT, Vezi BZ, Keren A, et al. Predictors of fracture risk of a small caliber implantable cardioverter defibrillator lead. Pacing Clin Electrophysiol. 2010; 33(4): 437–443.
- Arias MA, Domínguez-Pérez L, Toquero J, et al. [Sprint fidelis defibrillation lead: a nine-center experience in Spain]. Rev Esp Cardiol. 2011; 64(4): 312–318.
- Faulknier BA, Traub DM, Aktas MK, et al. Time-dependent risk of Fidelis lead failure. Am J Cardiol. 2010; 105(1): 95–99.
- Farwell D, Green MS, Lemery R, et al. Accelerating risk of Fidelis lead fracture. Heart Rhythm. 2008; 5(10): 1375–1379.
- Verlato R, Facchin D, Catanzariti D, et al. Clinical outcomes in patients with implantable cardioverter defibrillators and Sprint Fidelis leads. Heart. 2013; 99(11): 799–804.
- Parsonnet V, Roelke M. The cephalic vein cutdown versus subclavian puncture for pacemaker/ICD lead implantation. Pacing Clin Electrophysiol. 1999; 22(5): 695–697.
- Erkapic D, Duray GZ, Bauernfeind T, et al. Insulation defects of thin high-voltage ICD leads: an underestimated problem? J Cardiovasc Electrophysiol. 2011; 22(9): 1018–1022.
- Salgado R, Martín J, Martínez J, et al. Small-Caliber Lead Failure After Generator Exchange. J Cardiovasc Electrophysiol. 2016; 27(7): 846–850.
- Mehta NK, Taylor M, Kalbfleisch S. The Impact of Inappropriate Implantable Cardiac Defibrillator Shocks on Cardiovascular Morbidity and Mortality. Pacing Clin Electrophysiol. 2016; 39(8): 858–862.
- Yang XW, Hua W, Ding LG, et al. OptiVol fluid index predicts acute decompensation of heart failure with a high rate of unexplained events. J Geriatr Cardiol. 2013; 10(3): 253–257.